Share

HALT: "Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-Addicted Lung Tumours"

Project objectives

HALT is a clinical trial being conducted to test whether stereotactic body radiotherapy (SBRT) can prolong the disease-free interval in patients with advanced oncogene-addicted lung cancer undergoing treatment with drugs called tyrosine inhibitors. -kinases (tyrosine kinase inhibitors, TKIs).

Start and end date

24 October 2019 - In progress

Project Manager

Sara Ramella - Principal Investigator

Coordinating institution of the project

Promoter of the study: the EORTC (European Organization for Research and Treatment of Cancer).
The National Coordinator is the S. Luigi Gonzaga - University of Turin.

Other Institutions involved

  • “Santa Maria della Misericordia” University Hospital of Udine
  • Bellaria Hospital in Bologna, the AUSL Romagna 
  • Santa Maria delle Croci Hospital in Ravenna.
magnifiercrossmenuchevron-downchevron-leftchevron-right